This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clincial Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
There are currently 18 open trials.
In 114 locations
What is a Clinical Trial?
There are currently 18 open trials
- TAS-120 for refractory myeloma patients with FGF/FGFR abnormalities
- Carfilzomib, thalidomide and dexamethasone in relapsed AL amyloidosis (CATALYST trial)
- Isatuximab in combination with pomalidomide and dexamethasone (ICARIA-MM trial)
- CC-220 monotherapy and combination for relapsed and refractory myeloma patients
- MUK eleven (Reolysin trial)
- Myeloma XII (ACCoRd)
- Venetoclax in combination with bortezomib and dexamethasone
- Durvalumab and daratumumab for relapsed and refractory myeloma patients (FUSIONMM-003 trial)
- Ixazomib and dexamethasone for relapsed or refractory AL amyloidosis patients (TOURMALINE-AL1)
- Buparlisib in combination with bortezomib (BUBBLE trial)
- Early access treatment with daratumumab
- MUK seven
- MUK Eight
- Daratumumab combination for newly diagnosed myeloma patients
- Carfilzomib for newly diagnosed patients prior to stem cell transplant (CARDAMON trial)
- Bendamustine combination for newly diagnosed myeloma patients with kidney impairment (OPTIMAL trial)
- GSK2857916 trial
- GSK525762 trial
Trial Title:
TAS-120 for refractory myeloma patients with FGF/FGFR abnormalities
Treatments:
TAS-120
Myeloma stage:
Refractory
Trial phase:
II
Summary:
The purpose of this trial is to determine the safety and efficacy of TAS-120 in refractory myeloma patients who have fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) abnormalities.
Genetic abnormalities that affect the FGF/FGFR signalling pathway are linked to many cancers including myeloma. TAS-120 is an inhibitor of FGFR and so is being researched as a myeloma treatment.
Locations:
Sarah Cannon Research Institute, London
Who can enter the study?:
Myeloma patients with confirmed genetic abnormalities within FGF/FGFR, for example amplification, mutation or translocation, who have not responded to any previous standard treatments.
What's involved?:
TAS-120 capsules are taken by mouth for a 21-day cycle.
Patients will be required to attend outpatient clinics for regular check-ups and blood tests.
Clinical Information
(for Medical Professionals):
This study is investigating the efficacy of TAS-120 in myeloma patients with fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) abnormalities who are refractory to all standard treatments.
For more information, click here
Find out more: